Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 42(4); December 2010
Prev issue Next issue
Original Articles
Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
Kyung Kee Baek, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun
Cancer Res Treat. 2010;42(4):185-190.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.185
AbstractAbstract PDFPubReaderePub
Purpose

Oxaliplatin-induced chronic peripheral neurotoxicity (OXCPN) manifests as a loss of sensation and dysesthesia in the distal extremities, which may impair daily activities and increase in incidence with the amount of oxaliplatin delivered. The variation in the reported incidence and severity of OXCPN may be a consequence of differences in the baseline characteristics of patients.

Materials and Methods

This was a prospective study (ClinicalTrials.gov, NCT00977717) in which OXCPN was recorded for all consecutive colon cancer patients treated at Samsung Medical Center (Seoul, Korea) with oxaliplatin-based combination chemotherapy. The primary endpoint was the incidence of severe OXCPN (grade 2 lasting for >7 days, or grade 3). The association of severe OXCPN and pretreatment parameters was evaluated using a multivariate regression model.

Results

Between Jan 2008 and Feb 2010, 100 patients treated with adjuvant folinic acid/fluorouracil plus oxaliplatin (FOLFOX) and 266 patients treated with capecitabine plus oxaliplatin (XELOX) or FOLFOX for advanced disease were registered into our study. The median cumulative dose of oxaliplatin was 796 mg/m2 (range, 85 to 1,583 mg/m2). Severe OXCPN was observed in 126 (34%) patients. Overall, 43 patients discontinued chemotherapy due to toxicity: 23 without severe OXCPN and 20 with severe OXCPN. In univariate analysis, severe OXCPN was frequently observed in patients with age ≥55 years (p<0.01), stage II or III (p<0.01), adjuvant setting (p=0.01), FOLFOX (p<0.01), performance status of 0 (p=0.02), and those with no prior chemotherapy (p<0.01). In a multivariate regression model, the number of chemotherapy cycles and the cumulative oxaliplatin dose were not associated with the development of severe OXCPN.

Conclusion

We failed to find a significant association between patient characteristics at baseline and the development of severe OXCPN after oxaliplatin-based combination chemotherapy. Pharmacogenomic profiling using genome-wide association study in these patients is underway.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution
    Jierong Han, Hengzhou Lai, Wenyuan Li, Huarui Liao, Chong Xiao, Xueke Li, Fengming You, Jing Guo
    Journal of Ethnopharmacology.2024; 326: 117735.     CrossRef
  • Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment
    Zhe Li, Xin Qiao, Xiao-Meng Liu, Shu-Hao Shi, Xin Qiao, Jing-Yuan Xu
    European Journal of Medicinal Chemistry.2023; 250: 115233.     CrossRef
  • Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
    Yu Mei, Xijia Feng, Tienan Feng, Min Yan, Zhenggang Zhu, Tian Li, Zhenglun Zhu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
    Roser Velasco, Montserrat Alemany, Macarena Villagrán, Andreas A. Argyriou
    Journal of Personalized Medicine.2021; 11(7): 669.     CrossRef
  • The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey
    Nadeen T Ali, Amel A Mohamed, Bashir A Yousef
    Asia-Pacific Journal of Oncology Nursing.2020; 7(3): 266.     CrossRef
  • Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects
    Ginah Nightingale, Rowena Schwartz, Ekaterina Kachur, Brianne N. Dixon, Christine Cote, Ashley Barlow, Brooke Barlow, Patrick Medina
    Journal of Geriatric Oncology.2019; 10(1): 4.     CrossRef
  • Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial
    Se Hoon Park, Jeeyun Lee, Tae Sung Sohn, Do Hoon Lim, Kyoung-Mee Kim, Ji Yeong An, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Su Jin Lee, Seung Tae Kim, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
    Precision and Future Medicine.2019; 3(1): 24.     CrossRef
  • Oxaliplatin‐induced enteric neuronal loss and intestinal dysfunction is prevented by co‐treatment with BGP‐15
    Rachel M McQuade, Vanesa Stojanovska, Rhian Stavely, Cara Timpani, Aaron C Petersen, Raquel Abalo, Joel C Bornstein, Emma Rybalka, Kulmira Nurgali
    British Journal of Pharmacology.2018; 175(4): 656.     CrossRef
  • Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
    Akie Watanabe, Chang Cheng Yang, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin‐induced peripheral neuropathy in Taiwanese patients with colorectal cancer
    Shu‐Yi Hsu, Wen‐Shih Huang, Shu‐Hui Lee, Tsui‐Ping Chu, Yung‐Chang Lin, Chang‐Hsien Lu, Randal D. Beaton, Sui‐Whi Jane
    European Journal of Cancer Care.2018; : e12976.     CrossRef
  • Factors associated with the development and severity of oxaliplatin‐induced peripheral neuropathy: a systematic review
    Jeremy N. Pulvers, Gavin Marx
    Asia-Pacific Journal of Clinical Oncology.2017; 13(6): 345.     CrossRef
  • Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy
    Kelly A Aromolaran, Peter A Goldstein
    Molecular Pain.2017;[Epub]     CrossRef
  • ALA-induced photodynamic effect on vitality, apoptosis, and secretion of vascular endothelial growth factor (VEGF) by colon cancer cells in normoxic environment in vitro
    A. Kawczyk-Krupka, K. Sieroń-Stołtny, W. Latos, Z.P. Czuba, B. Kwiatek, M. Potempa, K. Wasilewska, W. Król, A. Stanek
    Photodiagnosis and Photodynamic Therapy.2016; 13: 308.     CrossRef
  • ALA-induced photodynamic effect on viability, apoptosis and secretion of S100 protein, secreted by colon cancer cells in vitro
    Aleksandra Kawczyk-Krupka, Wojciech Latos, Magdalena Latos, Zenon P. Czuba, Aleksander Sieroń
    Photodiagnosis and Photodynamic Therapy.2016; 15: 218.     CrossRef
  • ALA-mediated photodynamic effect on apoptosis induction and secretion of macrophage migration inhibitory factor (MIF) and of monocyte chemotactic protein (MCP-1) by colon cancer cells in normoxia and in hypoxia-like conditions in vitro
    Aleksandra Kawczyk-Krupka, Andrzej M. Bugaj, Wojciech Latos, Katarzyna Wawrzyniec, Piotr Oleś, Anna Mertas, Zenon Czuba, Wojciech Król, Karolina Sieroń-Stołtny, Aleksander Sieroń
    Photodiagnosis and Photodynamic Therapy.2015; 12(1): 27.     CrossRef
  • The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy
    Joanna E. Fardell, Janette Vardy, Lauren A. Monds, Ian N. Johnston
    Behavioural Brain Research.2015; 291: 80.     CrossRef
  • Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)
    Andreas Argyriou
    Toxics.2015; 3(2): 187.     CrossRef
  • α7 Nicotinic Receptor Promotes the Neuroprotective Functions of Astrocytes against Oxaliplatin Neurotoxicity
    Lorenzo Di Cesare Mannelli, Barbara Tenci, Matteo Zanardelli, Paola Failli, Carla Ghelardini
    Neural Plasticity.2015; 2015: 1.     CrossRef
  • Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran
    Ali Shahriari-Ahmadi, Ali Fahimi, Mehrdad Payandeh, Masoud Sadeghi
    Asian Pacific Journal of Cancer Prevention.2015; 16(17): 7603.     CrossRef
  • Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    R. Velasco, J. Bruna, C. Briani, A. A. Argyriou, G. Cavaletti, P. Alberti, B. Frigeni, M. Cacciavillani, S. Lonardi, D. Cortinovis, M. Cazzaniga, C. Santos, H. P. Kalofonos
    Journal of Neurology, Neurosurgery & Psychiatry.2014; 85(4): 392.     CrossRef
  • Chemotherapy-induced neuropathy: A comprehensive survey
    N.C. Miltenburg, W. Boogerd
    Cancer Treatment Reviews.2014; 40(7): 872.     CrossRef
  • Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
    A. Custodio, J. Moreno-Rubio, J. Aparicio, J. Gallego-Plazas, R. Yaya, J. Maurel, O. Higuera, E. Burgos, D. Ramos, A. Calatrava, E. Andrada, R. López, V. Moreno, R. Madero, P. Cejas, J. Feliu
    Annals of Oncology.2014; 25(2): 398.     CrossRef
  • Oxaliplatin Neurotoxicity
    Roser Velasco, Jordi Bruna
    Current Colorectal Cancer Reports.2014; 10(3): 303.     CrossRef
  • Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
    Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali
    International Journal of Clinical Medicine.2014; 05(07): 393.     CrossRef
  • Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study
    Jenny E. Drott, Hans Starkhammar, Sussanne Börjeson, Carina M. Berterö
    Open Journal of Nursing.2014; 04(04): 265.     CrossRef
  • Advanced age and liability to oxaliplatin‐induced peripheral neuropathy: post hoc analysis of a prospective study
    A. A. Argyriou, C. Briani, G. Cavaletti, J. Bruna, P. Alberti, R. Velasco, S. Lonardi, D. Cortinovis, M. Cazzaniga, M. Campagnolo, C. Santos, H. P. Kalofonos
    European Journal of Neurology.2013; 20(5): 788.     CrossRef
  • Neuropatia Periférica em Pacientes com Câncer Colorretal em Tratamento com Oxaliplatina
    Helena Maria de Cerqueira Mathias, Maria Cecília Mathias Machado, Adriano Celso Rodrigues
    Revista Neurociências.2013; 21(3): 435.     CrossRef
  • Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients
    Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park
    Cancer.2012; 118(11): 2828.     CrossRef
  • Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
    A.A. Argyriou, R. Velasco, C. Briani, G. Cavaletti, J. Bruna, P. Alberti, M. Cacciavillani, S. Lonardi, C. Santos, D. Cortinovis, M. Cazzaniga, H.P. Kalofonos
    Annals of Oncology.2012; 23(12): 3116.     CrossRef
  • Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial
    R. X. Zhang, Z. H. Lu, D. S. Wan, X. J. Wu, P. R. Ding, L. H. Kong, Z. Z. Pan, G. Chen
    International Journal of Colorectal Disease.2012; 27(12): 1645.     CrossRef
  • 12,094 View
  • 81 Download
  • 30 Crossref
Close layer
Results of Colorectal Cancer Screening of the National Cancer Screening Program in Korea, 2008
Jung Im Shim, Yeonju Kim, Mi Ah Han, Hoo-Yeon Lee, Kui Sun Choi, Jae Kwan Jun, Eun-Cheol Park
Cancer Res Treat. 2010;42(4):191-198.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.191
AbstractAbstract PDFPubReaderePub
Purpose

This study aims to investigate the current situation of national colorectal cancer screening by analyzing participation rates, positive rates of screening methods and screening rate of secondary screening tests in colorectal screening of the national cancer screening program in 2008.

Materials and Methods

With database about target population and screened individuals of the national cancer screening program, the results of target population and participants of colorectal cancer screening in 2008 were analyzed. Among adults aged over 50 years of medical aid and beneficiaries of national health insurance paying lower 50% premiums in the total subscribers, 4,640,365 were target population of colorectal cancer screening and the data of 984,915 undergoing fecal occult blood test (FOBT) as a primary screening were analyzed.

Results

The colorectal cancer screening rate was 21.2% and the rates of national health insurance subscribers, females and the elderly aged 60-64 years were higher than those of others. The recipients with a positive result in FOBT recorded approximately 7.5%. Medical aid beneficiaries (7.9%), males (8.8%) and seniors aged over 75 years (9.1%) showed higher positive rates than the average one. Out of the FOBT positive recipients, 43.0% took a secondary screening and the rate undergoing colonoscopy (31.4%) was higher than that of doing double-contrast barium enema test (11.6%).

Conclusion

Colorectal cancer screening rate of medical aid beneficiaries and people paying lower 50% premiums among national health insurance subscribers, was different according to demographic characters (gender, age and types of health insurance). This finding meant that screening for the vulnerable needed to be encouraged by considering socio-demographic characters. Additionally, more efforts were necessary to increase the secondary screening rate of people with a positive result in primary one.

Citations

Citations to this article as recorded by  
  • Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors
    Caitlin C. Murphy, Timothy A. Zaki
    Nature Reviews Gastroenterology & Hepatology.2024; 21(1): 25.     CrossRef
  • A risk scoring system for advanced colorectal neoplasia in high-risk participants to improve current colorectal cancer screening in Tianjin, China
    Zhen Yuan, Shuyuan Wang, Zhaoce Liu, Yanfei Liu, Yuqi Wang, Youkui Han, Weifeng Gao, Xinyu Liu, Hongzhou Li, Qinghuai Zhang, Hong Ma, Junying Wang, Xiaomeng Wei, Xipeng Zhang, Wei Cui, Chunze Zhang
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
    Yoonsuk Jung, Eui Im, Jinhee Lee, Hyeah Lee, Changmo Moon
    Journal of Personalized Medicine.2021; 11(6): 497.     CrossRef
  • Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region
    Han-Mo Chiu, Chiu-Wen Su, Weng-Feng Hsu, Grace Hsiao-Hsuan Jen, Chen-Yang Hsu, Sam Li-Sheng Chen, Hsiu-Hsi Chen
    Preventive Medicine.2021; 151: 106622.     CrossRef
  • Incidence of Colorectal Cancer and Adenomatous Polyps After a Two-Step Screening in Isfahan Province, Iran in 2018
    Moslem Taheri Soodejani, Hossein Mirzaei, Marzieh Mahmoodi Manesh, Seyyed Mohammad Tabatabaei, Azimeh Ghaderi
    Journal of Gastrointestinal Cancer.2020; 51(3): 850.     CrossRef
  • The prognoses and postoperative outcomes of patients with both colorectal cancer and liver cirrhosis based on a nationwide cohort in Korea
    Nari Shin, Eon Chul Han, Sungho Won, Seung-Bum Ryoo, Eun Kyung Choe, Byung Kwan Park, Kyu Joo Park
    Annals of Surgical Treatment and Research.2020; 99(2): 82.     CrossRef
  • Feasibility of CYFRA 21‐1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45
    Do Hyoung Lim, Jai Hyuen Lee, Jong Wan Kim
    Journal of Clinical Laboratory Analysis.2018;[Epub]     CrossRef
  • Risk and Characteristics of Postcolonoscopy Interval Colorectal Cancer after a Positive Fecal Test: A Nationwide Population-Based Study in Korea
    Chang Kyun Lee, Kui Son Choi, Chang Soo Eun, Dong-Il Park, Dong Soo Han, Minjoo Yoon, Mina Suh, Jae Kwan Jun
    Cancer Research and Treatment.2018; 50(1): 50.     CrossRef
  • Associations of perceived risk and cancer worry for colorectal cancer with screening behaviour
    Eunji Choi, Yoon Young Lee, Mina Suh, Boyoung Park, Jae Kwan Jun, Yeol Kim, Kui Son Choi
    Journal of Health Psychology.2018; 23(6): 840.     CrossRef
  • Stages of Adoption for Fecal Occult Blood Test and Colonoscopy Tests for Colorectal Cancer Screening in Korea
    Nhung Cam Bui, Ha Na Cho, Yoon Young Lee, Mina Suh, Boyoung Park, Jae Kwan Jun, Yeol Kim, Kui Son Choi
    Cancer Research and Treatment.2018; 50(2): 416.     CrossRef
  • Risk of Interval Cancer in Fecal Immunochemical Test Screening Significantly Higher During the Summer Months: Results from the National Cancer Screening Program in Korea
    Jae Myung Cha, Mina Suh, Min Seob Kwak, Na Young Sung, Kui Son Choi, Boyoung Park, Jae Kwan Jun, Sang-Hyun Hwang, Do-Hoon Lee, Byung Chang Kim, You Kyoung Lee, Dong Soo Han
    American Journal of Gastroenterology.2018; 113(4): 611.     CrossRef
  • Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013
    Ja Min Byun, Young Jin Kim, Taemi Youk, John Jeongseok Yang, Jongha Yoo, Tae Sung Park
    Annals of Hematology.2017; 96(3): 373.     CrossRef
  • Fecal Occult Blood Test Results of the National Colorectal Cancer Screening Program in South Korea (2006–2013)
    John Hoon Rim, Taemi Youk, Jung Gu Kang, Byung Kyu Park, Heon Yung Gee, Jeong-Ho Kim, Jongha Yoo
    Scientific Reports.2017;[Epub]     CrossRef
  • Absence of GNAS Mutation in Colorectal Carcinogenesis
    Hyunsu Lee, Boo-Mi La, IlSeon Hwang, Yu-Na Kang, In-Jang Choi, Jae-Ho Lee
    Tumori Journal.2017; 103(2): 209.     CrossRef
  • Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide
    CM de Klerk, S Gupta, E Dekker, ML Essink-Bot
    Gut.2017; : gutjnl-2016-313311.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2013
    Mina Suh, Kui Son Choi, Boyoung Park, Yoon Young Lee, Jae Kwan Jun, Duk-Hyoung Lee, Yeol Kim
    Cancer Research and Treatment.2016; 48(1): 1.     CrossRef
  • A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms
    Han-Mo Chiu, Jessica Y.L. Ching, Kai Chun Wu, Rungsun Rerknimitr, Jingnan Li, Deng-Chiang Wu, Khean Lee Goh, Takahisa Matsuda, Hyun-Soo Kim, Rupert Leong, Khay Guan Yeoh, Vui Heng Chong, Jose D. Sollano, Furqaan Ahmed, Jayaram Menon, Joseph J.Y. Sung
    Gastroenterology.2016; 150(3): 617.     CrossRef
  • Effectiveness of Intraluminal Air Decompression on Postcolonoscopic Pain According to Reinsertion Site
    Young-Jin Sur, Jung-Hyun Kim, Seung-Jin Jung, Dong-Won Lee, Sang-Hyun Cho, Ryang-Pyo Kim, Tae-Wan Kim, Hyeon-Guk Shin, A-Ram Hong, Hyun-Woo Kwon
    Korean Journal of Family Medicine.2016; 37(3): 156.     CrossRef
  • Outreach and Inreach Organized Service Screening Programs for Colorectal Cancer
    Chu-Kuang Chou, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Han-Mo Chiu, Shu-Lin Chuang, Tsung-Hsien Chiang, Ming-Shiang Wu, Chien-Yuan Wu, Shu-Li Chia, Yi-Chia Lee, Shu-Ti Chiou, Hsiu-Hsi Chen, Nathan A. Ellis
    PLOS ONE.2016; 11(5): e0155276.     CrossRef
  • Disparities in prevalence, location, and shape characteristics of colorectal neoplasia between South Korean and U.S. patients
    Jae Myung Cha, Richard A. Kozarek, Danielle La Selva, Michael Gluck, Andrew Ross, Michael Chiorean, Johannes Koch, Otto S. Lin
    Gastrointestinal Endoscopy.2015; 82(6): 1080.     CrossRef
  • Non-invasive screening for colorectal cancer in Asia
    Han-Mo Chiu, Li-Chun Chang, Wen-Feng Hsu, Chu-Kuang Chou, Ming-Shiang Wu
    Best Practice & Research Clinical Gastroenterology.2015; 29(6): 953.     CrossRef
  • Colorectal cancer screening: a global overview of existing programmes
    Eline H Schreuders, Arlinda Ruco, Linda Rabeneck, Robert E Schoen, Joseph J Y Sung, Graeme P Young, Ernst J Kuipers
    Gut.2015; 64(10): 1637.     CrossRef
  • Changing trends in colorectal cancer in the Republic of Korea: contrast with Japan
    Minjoo Yoon, Nicholas Kim, Byungho Nam, Jungnam Joo, Moran Ki
    Epidemiology and Health.2015; 37: e2015038.     CrossRef
  • Preferences and Acceptance of Colorectal Cancer Screening in Thailand
    Udomsak Saengow, Virasakdi Chongsuwiwatvong, Alan Geater, Stephen Birch
    Asian Pacific Journal of Cancer Prevention.2015; 16(6): 2269.     CrossRef
  • Genetic Characteristics of Mitochondrial DNA Was Associated with Colorectal Carcinogenesis and Its Prognosis
    Jae-Ho Lee, Ilseon Hwang, Yu-Na Kang, In-Jang Choi, Dae-Kwang Kim, Anthony W.I. Lo
    PLOS ONE.2015; 10(3): e0118612.     CrossRef
  • Economic Burden of Colorectal Cancer in Korea
    Ju-Young Byun, Seok-Jun Yoon, In-Hwan Oh, Young Ae Kim, Hye-Young Seo, Yo-Han Lee
    Journal of Preventive Medicine and Public Health.2014; 47(2): 84.     CrossRef
  • Sorting out measures and definitions of screening participation to improve comparability: The example of colorectal cancer
    Jean-Luc Bulliard, Montse Garcia, Johannes Blom, Carlo Senore, Verna Mai, Carrie Klabunde
    European Journal of Cancer.2014; 50(2): 434.     CrossRef
  • Tests and investigations for colorectal cancer screening
    Magdalen R.R. Carroll, Helen E. Seaman, Stephen P. Halloran
    Clinical Biochemistry.2014; 47(10-11): 921.     CrossRef
  • Factors associated with adherence to fecal occult blood testing for colorectal cancer screening among adults in the Republic of Korea
    Nayoung Bae, Sunhee Park, Sungwon Lim
    European Journal of Oncology Nursing.2014; 18(1): 72.     CrossRef
  • Barriers to Cancer Screening among Medical Aid Program Recipients in the Republic of Korea: A Qualitative Study
    Yoon Young Lee, Jae Kwan Jun, Mina Suh, BoYoung Park, Yeol Kim, Kui Son Choi
    Asian Pacific Journal of Cancer Prevention.2014; 15(2): 589.     CrossRef
  • Factors Associated with Organized and Opportunistic Cancer Screening: Results of the Korea National Health and Nutrition Examination Survey (KNHANES) 2007-2011
    Minsun Kang, Ki-Bong Yoo, Eun-Cheol Park, Kisung Kwon, Gaeun Kim, Doo Ree Kim, Jeoung A Kwon
    Asian Pacific Journal of Cancer Prevention.2014; 15(7): 3279.     CrossRef
  • Organised colorectal cancer screening in Lampang Province, Thailand: preliminary results from a pilot implementation programme
    Thiravud Khuhaprema, Suleeporn Sangrajrang, Somkiat Lalitwongsa, Vanida Chokvanitphong, Tawarat Raunroadroong, Tawee Ratanachu-ek, Richard Muwonge, Eric Lucas, Christopher Wild, Rengaswamy Sankaranarayanan
    BMJ Open.2014; 4(1): e003671.     CrossRef
  • Cancer Screening in Korea, 2012: Results from the Korean National Cancer Screening Survey
    Mina Suh, Kui Son Choi, Yoon Young Lee, Boyoung Park, Jae Kwan Jun
    Asian Pacific Journal of Cancer Prevention.2013; 14(11): 6459.     CrossRef
  • Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
    Digestive Diseases and Sciences.2013; 58(11): 3256.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey, 2004-2012
    Mina Suh, Kui Son Choi, Yoon Young Lee, Jae Kwan Jun
    Cancer Research and Treatment.2013; 45(2): 86.     CrossRef
  • Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy?
    Ja Sung Choi, Jin Yi Choi, Hyeon Geun Cho, Ki Jun Han, Hee Man Kim, Jae Hee Cho, Yu Jin Kim
    Scandinavian Journal of Gastroenterology.2013; 48(6): 657.     CrossRef
  • Body Mass Index as a Predictor of Advanced Colorectal Neoplasia
    Hyuk Jin Kwon, Hee Jin Kim, Young Soo Park, Ji Hyun Lim, Kyoung Jun Park, Cheol Min Shin, Jin-Hyeok Hwang, Jin-Wook Kim, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee
    Journal of Cancer Prevention.2013; 18(2): 144.     CrossRef
  • Cancer Screening Status in Korea, 2011: Results from the Korean National Cancer Screening Survey
    Bo-Young Park, Kui-Son Choi, Yoon-Young Lee, Jae-Kwan Jun, Hong-Gwan Seo
    Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1187.     CrossRef
  • Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
    Digestive Diseases and Sciences.2012; 57(8): 2178.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011
    Boyoung Park, Kui Son Choi, Yoon Young Lee, Jae Kwan Jun, Hong Gwan Seo
    Cancer Research and Treatment.2012; 44(2): 113.     CrossRef
  • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
    Bo In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Young-Ho Kim, Dong Il Park, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
    The Korean Journal of Gastroenterology.2012; 59(2): 65.     CrossRef
  • First-Degree Relatives of Colorectal Cancer Patients Are Likely to Show Advanced Colorectal Neoplasia despite a Negative Fecal Immunochemical Test
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim
    Digestion.2012; 86(4): 283.     CrossRef
  • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
    Bo In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Young-Ho Kim, Dong Il Park, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
    Intestinal Research.2012; 10(1): 67.     CrossRef
  • High‐frequency minisatellite instability of the mitochondrial genome in colorectal cancer tissue associated with clinicopathological values
    Sang Woo Lim, Hye Ran Kim, Hwan Young Kim, Jung Wook Huh, Young Jin Kim, Jong Hee Shin, Soon Pal Suh, Dong Wook Ryang, Hyeong Rok Kim, Myung Geun Shin
    International Journal of Cancer.2012; 131(6): 1332.     CrossRef
  • Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: A comparison of two invitation strategies
    Sofie Van Roosbroeck, Sarah Hoeck, Guido Van Hal
    Cancer Epidemiology.2012; 36(5): e317.     CrossRef
  • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
    Bo-In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Dong Il Park, Young-Ho Kim, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
    Clinical Endoscopy.2012; 45(1): 25.     CrossRef
  • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
    Bo In Lee, Sung Pil Hong, Seong Eun Kim, Se Hyung Kim, Hyun Soo Kim, Sung Noh Hong, Dong Hoon Yang, Sung Jae Shin, Suck Ho Lee, Young Ho Kim, Dong Il Park, Hyun Jung Kim, Suk Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
    Journal of the Korean Society of Radiology.2012; 66(4): 385.     CrossRef
  • Telephone Reminder Call in Addition to Mailing Notification Improved the Acceptance Rate of Colonoscopy in Patients with a Positive Fecal Immunochemical Test
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park
    Digestive Diseases and Sciences.2011; 56(11): 3137.     CrossRef
  • 15,074 View
  • 107 Download
  • 48 Crossref
Close layer
Trends of Mammography Use in a National Breast Cancer Screening Program, 2004-2008
Sun Mi Lim, Hoo-Yeon Lee, Kui Son Choi, Jae Kwan Jun, Eun-Cheol Park, Yeonju Kim, Mi Ah Han, Dong Kwan Oh, Jung Im Shim
Cancer Res Treat. 2010;42(4):199-202.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.199
AbstractAbstract PDFPubReaderePub
Purpose

Korea started breast cancer screening as part of the National Cancer Screening Program (NCSP) in 1999. In order to identify under-served groups, we investigated mammography uptake in the National Breast Cancer Screening Program.

Materials and Methods

The study population was participants in the National Breast Cancer Screening Program from 2004 to 2008. We analyzed participation rates by insurance type, age group, and area of residence.

Results

Total participation rates for breast cancer screening increased from 18.2% in 2004 to 35.0% in 2008. The participation rate in the group aged 60 to 69 years showed the greatest increase, 21.3%, among the four age groups. Although the screening rate increased continuously, the participation rate of the Medical Aid Program (MAP) group was low compared to the National Health Insurance (NHI) group. Moreover, the increasing trend of mammography uptake in the MAP group was much lower than that of the NHI group.

Conclusion

The participation rate for breast cancer screening in the NCSP in Korea has increased. However, the participation rate in mammography among MAP recipients is still lower than that of NHI beneficiaries. To increase mammography uptake, it is important to make it available to everyone by ensuring inclusion of all population subgroups.

Citations

Citations to this article as recorded by  
  • Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis
    Rebecca Mottram, Wendy Lynn Knerr, Daniel Gallacher, Hannah Fraser, Lena Al-Khudairy, Abimbola Ayorinde, Sian Williamson, Chidozie Nduka, Olalekan A Uthman, Samantha Johnson, Alexander Tsertsvadze, Christopher Stinton, Sian Taylor-Phillips, Aileen Clarke
    BMJ Open.2021; 11(11): e046660.     CrossRef
  • Spectrum of very early breast cancer in a setting without organised screening
    N Bhoo-Pathy, S Subramaniam, N A Taib, M Hartman, Z Alias, G-H Tan, R I Ibrahim, C-H Yip, H M Verkooijen
    British Journal of Cancer.2014; 110(9): 2187.     CrossRef
  • Factors Associated with Organized and Opportunistic Cancer Screening: Results of the Korea National Health and Nutrition Examination Survey (KNHANES) 2007-2011
    Minsun Kang, Ki-Bong Yoo, Eun-Cheol Park, Kisung Kwon, Gaeun Kim, Doo Ree Kim, Jeoung A Kwon
    Asian Pacific Journal of Cancer Prevention.2014; 15(7): 3279.     CrossRef
  • Attendance of the fourth (2008–2009) screening round of the Hungarian organized, nationwide breast cancer screening program
    Imre Boncz, Lajos Döbrőssy, Zoltán Péntek, Attila Kovács, András Budai, László Imre, Réka Vajda, Andor Sebestyén
    Orvosi Hetilap.2013; 154(50): 1975.     CrossRef
  • Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes
    Jiyoung Kim, SeKyung Lee, SooYoun Bae, Min-Young Choi, Jeonghui Lee, Seung Pil Jung, Sangmin Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang
    Breast Cancer Research and Treatment.2012; 131(2): 527.     CrossRef
  • Satisfaction in the National Cancer Screening Program for Breast Cancer with and without Clinical Breast Examination
    Mi-Ah Han, Jae-Kwan Jun, Kui-Son Choi, Eun-Cheol Park, Hoo-Yeon Lee
    Asian Pacific Journal of Cancer Prevention.2012; 13(1): 63.     CrossRef
  • Time to follow up after an abnormal finding in organized gastric cancer screening in Korea
    Hoo-Yeon Lee, Kui Son Choi, Jae Kwan Jun, Myung-Il Hahm, Eun-Cheol Park
    BMC Cancer.2012;[Epub]     CrossRef
  • Risk Factors and Control Strategies for the Rapidly Rising Rate of Breast Cancer in Korea
    Sue K. Park, Yeonju Kim, Daehee Kang, En-Joo Jung, Keun-Young Yoo
    Journal of Breast Cancer.2011; 14(2): 79.     CrossRef
  • 9,892 View
  • 53 Download
  • 8 Crossref
Close layer
Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era
Nae Yu Kim, Jong Mu Sun, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jin-Wook Kim, Sook-Hyang Jeong, Jong Seok Lee
Cancer Res Treat. 2010;42(4):203-209.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.203
AbstractAbstract PDFPubReaderePub
Purpose

Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses.

Materials and Methods

The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS.

Results

Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP.

Conclusion

Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.

Citations

Citations to this article as recorded by  
  • circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR‐338‐5p/IL‐7 pathway
    Siyu Zhang, Jun Ma, Tingdong Yu, Zhengrui Song, Wan Yee Lau, Yong Zha
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Inhibition of mycobacteria proliferation in macrophages by low cisplatin concentration through phosphorylated p53-related apoptosis pathway
    Jiajia Bao, Yonglin He, Chun Yang, Nan Lu, Anlong Li, Sijia Gao, Felycia Fernanda Hosyanto, Jialing Tang, Junzhuo Si, Xia Tang, Huichao Fu, Lei Xu, Harish Chandra
    PLOS ONE.2023; 18(1): e0281170.     CrossRef
  • A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma
    Yao‐Chung Liu, Chien‐Wei Su, Po‐Shen Ko, Rheun‐Chuan Lee, Chia‐Jen Liu, Yi‐Hsiang Huang, Jyh‐Pyng Gau, Jin‐Hwang Liu
    Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 19.     CrossRef
  • A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy
    Vincent Manceau, Xavier Palard, Yan Rolland, March Pracht, Samuel Le Sourd, Sophie Laffont, Karim Boudjema, Astride Lievre, Habiba Mesbah, Laure-Anne Haumont, Laurence Lenoir, Vanessa Brun, Thomas Uguen, Julien Edeline, Etienne Garin
    European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(10): 1731.     CrossRef
  • Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1
    Jun Qin, Meng Luo, Haixin Qian, Wei Chen
    Gene.2014; 538(2): 342.     CrossRef
  • The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines
    EUN-YOUNG MIN, IN-HYE KIM, JUNGIM LEE, EUN-YOUNG KIM, YOUN-HEE CHOI, TAEK-JEONG NAM
    International Journal of Oncology.2014; 45(1): 47.     CrossRef
  • The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation
    Vasilis P. Androutsopoulos, Demetrios A. Spandidos
    The Journal of Nutritional Biochemistry.2013; 24(2): 496.     CrossRef
  • Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
    Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura
    Cancers.2012; 4(1): 165.     CrossRef
  • 9,505 View
  • 55 Download
  • 8 Crossref
Close layer
Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival
Sung-Hwan Kim, Mi Hyang Kwak, Sohee Park, Hak Jin Kim, Hyun-Sung Lee, Moon Soo Kim, Jong Mog Lee, Jae Ill Zo, Jung Sil Ro, Jin Soo Lee
Cancer Res Treat. 2010;42(4):210-216.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.210
AbstractAbstract PDFPubReaderePub
Purpose

We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade.

Materials and Methods

Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients.

Results

Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively.

Conclusion

Recurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.

Citations

Citations to this article as recorded by  
  • Pericardiocentesis versus window formation in malignant pericardial effusion: trends and outcomes
    Jaeoh Lee, Kyu Kim, Seo-Yeon Gwak, Hyun-Jung Lee, Iksung Cho, Geu-Ru Hong, Jong-Won Ha, Chi Young Shim
    Heart.2024; 110(12): 863.     CrossRef
  • Pericardial effusion in oncological patients: current knowledge and principles of management
    S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto, P. Ameri
    Cardio-Oncology.2024;[Epub]     CrossRef
  • Malignant Pericardial Effusion: A Systematic Review
    Sarah E. Mudra, Danny Rayes, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Charalampos Charalampous, Kazi A. Kalam, Alveena Syed, Muhammad Majid, Mary Schleicher, Ankit Agrawal, Abdullah Yesilyaprak, Allan L. Klein
    CJC Open.2024; 6(8): 967.     CrossRef
  • A Case Report of Video-assisted Thoracoscopic Pericardiectomy for Postpericardiotomy Recurrent Loculated Pericardial Effusion
    Hao-Wen Chang, Chen-Liang Tsai
    Journal of Medical Sciences.2024; 44(5): 231.     CrossRef
  • Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017
    Andrija Matetic, Bonnie Ky, Eric H. Yang, Phyo K. Myint, Muhammad Rashid, Shelley Zieroth, Timir K. Paul, Ayman Elbadawi, Mamas A. Mamas
    Cancer Medicine.2023; 12(5): 5471.     CrossRef
  • Breast Cancer Complicated by Cardiac Tamponade in a Patient With Neurofibromatosis Type 1
    Narek Hakobyan, Nosakhare Ilerhunmwuwa, Henry O Aiwuyo, Ephrem Sedeta, Ifeanyi Uche, Mustafa Wasifuddin, Jamal C Perry
    Cureus.2023;[Epub]     CrossRef
  • Cardiac tamponade
    Yehuda Adler, Arsen D. Ristić, Massimo Imazio, Antonio Brucato, Sabine Pankuweit, Ivana Burazor, Petar M. Seferović, Jae K. Oh
    Nature Reviews Disease Primers.2023;[Epub]     CrossRef
  • Peritoneal Carcinoma Unveiling a Hidden Threat: A Case of Malignant Pericardial Effusion
    Mohammed Abusuliman, Amr M Mohamed, Anas Mahmoud, Tala Beliani, Ibrahim M Ismail-Sayed
    Cureus.2023;[Epub]     CrossRef
  • Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
    Varsha Chiruvella, Asad Ullah, Islam Elhelf, Nikhil Patel, Nagla Abdel Karim
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis
    Talha Ahmed, Elie Mouhayar, Juhee Song, Efstratios Koutroumpakis, Nicolas L. Palaskas, Syed Wamique Yusuf, Juan Lopez-Mattei, Saamir A. Hassan, Peter Kim, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Ara A. Vaporciyan, Stephen Swisher, Anita Deswal, Ce
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Malignant Cardiac Tamponade: A Complication of Untreated Breast Cancer
    Mohamed Ramzi Almajed, Mark S Obri, Wasih Kamran, Abigail Entz
    Cureus.2022;[Epub]     CrossRef
  • High frequency ultrasound‐guided pericardiocentesis performed in the sitting position: A novel apical approach
    Lei Zhang, Xue‐Fei Zhang, Zhao Liu, Ying Liu, Cun‐Li Guo, Hua Shao, Bo Li, Cui Zhang, Hui Jing, Wen Cheng
    Clinical Cardiology.2021; 44(8): 1106.     CrossRef
  • How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia
    Robin Jacob, Nicolas L. Palaskas, Juan Lopez-Mattei, Saamir Hassan, Peter Kim, Teodora Donisan, Dinu Valentin Balanescu, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
    JACC: CardioOncology.2021; 3(3): 452.     CrossRef
  • Pericardial Effusion and Cardiac Tamponade: Etiology and Evolution in the Contemporary Era
    Claudio Martins de Queiroz, Juliano Cardoso, Felix Ramires, Barbara Ianni, Viviane Tiemi Hotta, Charles Mady, Paula de Cassia Buck, Ricardo Ribeiro Dias, Luciano Nastari, Fábio Fernandes
    International Journal of Cardiovascular Sciences.2021; 34(5 Supl 1): 24.     CrossRef
  • The Effect of Lenvatinib in Patients with Thyroid Cancer with Pericardial Metastasis, Which Can Cause Cardiac Tamponade
    Keiichiro Okano, Akihito Arai, Satomi Ozawa, Hiroki Morimoto, Gaku Omura, Takahiro Tsujikawa, Shigeru Hirano
    Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).2021; 124(11): 1525.     CrossRef
  • Clinico‐cytopathologic analysis of 574 Pericardial Effusion Specimens: Application of the international system for reporting serous fluid cytopathology (ISRSFC) and long‐term clinical follow‐up
    Min Jeong Song, Uiree Jo, Ji‐Seon Jeong, Kyung‐Ja Cho, Gyungyub Gong, Yong Mee Cho, Joon Seon Song
    Cancer Medicine.2021; 10(24): 8899.     CrossRef
  • Oncologic Emergencies—The Old, the New, and the Deadly
    Krishna Thandra, Zuhair Salah, Sanjay Chawla
    Journal of Intensive Care Medicine.2020; 35(1): 3.     CrossRef
  • Acute Myeloid Leukemia Presenting as Effusive Constrictive Pericarditis
    Andrew Lutz, Erik B. Schelbert, Konstantinos Lontos, James Rossetti, William Katz
    CASE.2020; 4(2): 97.     CrossRef
  • State-of-the-art Review: Interventional Onco-Cardiology
    Bala Pushparaji, Konstantinos Marmagkiolis, Cameron K. Miller, Moez K. Aziz, Dinu V. Balanescu, Teodora Donisan, Nicolas Palaskas, Peter Kim, Juan Lopez-Mattei, Mehmet Cilingiroglu, Saamir A. Hassan, Cezar A. Iliescu
    Current Treatment Options in Cardiovascular Medicine.2020;[Epub]     CrossRef
  • In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening
    Cheng-Guang Wu, Francesca Chiovaro, Alessandra Curioni-Fontecedro, Ruben Casanova, Alex Soltermann
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes
    Massimo Imazio, Marzia Colopi, Gaetano Maria De Ferrari
    Heart.2020; 106(8): 569.     CrossRef
  • Update on diagnosis and management of neoplastic pericardial disease
    Stefano Avondo, Alessandro Andreis, Matteo Casula, Massimo Imazio
    Expert Review of Cardiovascular Therapy.2020; 18(9): 615.     CrossRef
  • Oncological Emergencies from Pathophysiology and Diagnosis to Treatment: A Narrative Review
    Ameneh Jafari, Mostafa Rezaei-Tavirani, Maryam Salimi, Reza Tavakkol, Zahra Jafari
    Social Work in Public Health.2020; 35(8): 689.     CrossRef
  • Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion
    So Ree Kim, Eun Kyoung Kim, Jinhyun Cho, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Seung Woo Park
    Journal of the American College of Cardiology.2020; 76(13): 1551.     CrossRef
  • Cancer prevalence, inpatient mortality and its predictors after pericardiocentesis
    İ̇dris Buğra ÇERİK, Ferhat DİNDAŞ, Emin KOYUN, İ̇brahim GÜL
    Cumhuriyet Medical Journal.2020;[Epub]     CrossRef
  • Neoplastic Pericardial Effusion: A Monocentric Retrospective Study
    Elisabetta Di Liso, Alice Menichetti, Maria Vittoria Dieci, Cristina Ghiotto, Alberto Banzato, Alessandra Bianchi, Giovanna Pintacuda, Marta Padovan, Floriana Nappo, Enrico Cumerlato, Federica Miglietta, Eleonora Mioranza, Giulia Zago, Luigi Corti, Valent
    Journal of Palliative Medicine.2019; 22(6): 691.     CrossRef
  • Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion
    Zhi Gang Hu, Ke Hu, Wen Xin Li, Fan Jun Zeng, Anna Halama
    PLOS ONE.2019; 14(5): e0217007.     CrossRef
  • Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma
    Bing Zhou, Lin Li, Dayou Shi, Tao Jiang, Guohui Xue, Jianping Xiong
    Indian Journal of Pathology and Microbiology.2019; 62(4): 566.     CrossRef
  • Cardiac Interventional Procedures in Cardio-Oncology Patients
    Teodora Donisan, Dinu Valentin Balanescu, Nicolas Palaskas, Juan Lopez-Mattei, Kaveh Karimzad, Peter Kim, Konstantinos Charitakis, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
    Cardiology Clinics.2019; 37(4): 469.     CrossRef
  • Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer
    Annop Lekhakul, Chalailak Assawakawintip, Eric R. Fenstad, Sorin V. Pislaru, Jeremy J. Thaden, Larry J. Sinak, Garvan C. Kane
    The American Journal of Cardiology.2018; 122(6): 1091.     CrossRef
  • The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion
    M. Szturmowicz, A. Pawlak-Cieślik, A. Fijałkowska, J. Gątarek, A. Skoczylas, M. Dybowska, K. Błasińska-Przerwa, R. Langfort, W. Tomkowski
    Supportive Care in Cancer.2017; 25(8): 2399.     CrossRef
  • Cardiovascular Complications of Cancer Therapy
    Hui-Ming Chang, Tochukwu M. Okwuosa, Tiziano Scarabelli, Rohit Moudgil, Edward T.H. Yeh
    Journal of the American College of Cardiology.2017; 70(20): 2552.     CrossRef
  • Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality
    Kirstine Kobberøe Søgaard, Dóra Körmendiné Farkas, Vera Ehrenstein, Krishnan Bhaskaran, Hans Erik Bøtker, Henrik Toft Sørensen
    Circulation.2017; 136(11): 996.     CrossRef
  • A Minimum Volume of More Than 60 mL Is Necessary for Adequate Cytologic Diagnosis of Malignant Pericardial Effusions
    Lisa M. Rooper, Syed Z. Ali, Matthew T. Olson
    American Journal of Clinical Pathology.2016; 145(1): 101.     CrossRef
  • Patient with Small Cell Lung Carcinoma and Suspected Right Upper Lobe Abscess Presenting with a Purulent Pericardial Effusion
    Khushboo Goel, Huthayfa Ateeli, Neil M. Ampel, Dena L’heureux
    American Journal of Case Reports.2016; 17: 523.     CrossRef
  • Surgical pericardial drainage in a series of 235 consecutive patients: an 8-year experience
    Ali Azari, Negar Manavifar, Veda Vakili, Leila Bigdelu
    Indian Journal of Thoracic and Cardiovascular Surgery.2016; 32(4): 250.     CrossRef
  • 2015 update on the diagnosis and management of neoplastic pericardial disease
    Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
    Expert Review of Cardiovascular Therapy.2015; 13(4): 377.     CrossRef
  • Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion
    Danielle El Haddad, Cezar Iliescu, Syed Wamique Yusuf, William Nassib William, Tarif H. Khair, Juhee Song, Elie N. Mouhayar
    Journal of the American College of Cardiology.2015; 66(10): 1119.     CrossRef
  • Haemodynamic Monitoring of Pericardial Effusion with Cardiac Tamponade in a Patient with Colorectal Cancer

    Journal of Anesthesia & Critical Care: Open Access.2015;[Epub]     CrossRef
  • Un traitement local ambitieux est-il envisageable en cas de métastases intrapéricardiques d’un cancer bronchique ?
    M. Riquet, C. Rivera, P. Mordant, É. Fabre
    Revue des Maladies Respiratoires.2014; 31(5): 439.     CrossRef
  • Les autres métastases
    A. Roche, C. Audigier-Valette
    Revue des Maladies Respiratoires Actualités.2014; 6(2): 173.     CrossRef
  • Análisis de las características clínicas, ecocardiográficas, microbiológicas y citopatológicas de derrames pericárdicos en un hospital de tercer nivel de atención
    José Martín Santa Cruz-Ruiz, Guillermo Sahagún-Sánchez, Diana González-Cabello, Nydia Sánchez-González
    Archivos de Cardiología de México.2014; 84(2): 86.     CrossRef
  • Infiltrative Cardiomyopathy and Pericardial Disease
    Syed Wamique Yusuf, Smita I. Negi, Daniel J. Lenihan
    Seminars in Oncology.2013; 40(2): 199.     CrossRef
  • Malignant Pericardial Effusion
    I. Burazor, M. Imazio, G. Markel, Y. Adler
    Cardiology.2013; 124(4): 224.     CrossRef
  • Prognostic relevance of pericardial effusion in patients with malignant diseases
    Tae-Dong Jeong, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi
    The Korean Journal of Hematology.2012; 47(3): 237.     CrossRef
  • Surgical properties and survival of a pericardial window via left minithoracotomy for benign and malignant pericardial tamponade in cancer patients
    Sezai Celik, Muharrem Celik, Bulent Aydemir, Handan Tanrıkulu, Tamer Okay, Nurşen Tanrikulu
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • Pericardial Diseases
    David M. Dudzinski, Gary S. Mak, Judy W. Hung
    Current Problems in Cardiology.2012; 37(3): 75.     CrossRef
  • Epidemiology, diagnosis and therapy of neoplastic pericarditis
    Chiara Lestuzzi
    Journal of Cardiovascular Echography.2011; 21(2): 86.     CrossRef
  • Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment
    Mark A. Lewis, Andrea Wahner Hendrickson, Timothy J. Moynihan
    CA: A Cancer Journal for Clinicians.2011; 61(5): 287.     CrossRef
  • 11,937 View
  • 94 Download
  • 49 Crossref
Close layer
Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
Joo Hoon Kim, Sun Young Rha, Chan Kim, Gun Min Kim, Sang Hyun Yoon, Ki Hyang Kim, Min Jae Kim, Joong Bae Ahn, Hyun Cheol Chung, Jae Kyung Roh, Hyo Song Kim
Cancer Res Treat. 2010;42(4):217-224.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.217
AbstractAbstract PDFPubReaderePub
Purpose

We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.

Materials and Methods

Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.

Results

Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).

Conclusion

Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.

Citations

Citations to this article as recorded by  
  • Metachronous or Synchronous Presentation of Acute Myeloid Leukemia and Lung Cancer: A Single Center Experience
    Başak Ünver Koluman, Atike Gökçen Demiray, Gulsum Akgun Cagliyan, Sibel Hacıoğlu, Nil Güler, Taner Durak, Yeliz Karakaya, Ferda Bir
    Akdeniz Medical Journal.2024;[Epub]     CrossRef
  • A Disguising Fast-Growing Metachronous Melanoma and COVID-19
    Alina Avram, Lucian G Scurtu, Mariana Costache, Olga Simionescu
    Cureus.2023;[Epub]     CrossRef
  • Solitary solutions to a metastasis model represented by two systems of coupled Riccati equations
    I. Timofejeva, T. Telksnys, Z. Navickas, R. Marcinkevicius, R. Mickevicius, M. Ragulskis
    Journal of King Saud University - Science.2023; 35(5): 102682.     CrossRef
  • Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report
    Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan
    Folia Medica.2023; 65(4): 693.     CrossRef
  • Features of synchronous and metachronous dual primary gastric and colorectal cancer
    Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
    World Journal of Gastrointestinal Oncology.2023; 15(11): 1864.     CrossRef
  • Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
    Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R.A.J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry,
    European Journal of Cancer.2022; 164: 18.     CrossRef
  • Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
    Tiuri E. Kroese, Nikita K.N. Jorritsma, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Jelle P. Ruurda, Peter S.N. van Rossum, Richard van Hillegersberg
    Clinical and Translational Radiation Oncology.2022; 37: 109.     CrossRef
  • Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report
    Risheng Huang, Zhijia Li, Shanshan Weng, Shenghao Wu
    Open Life Sciences.2022; 17(1): 1263.     CrossRef
  • A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
    Marta Pina, Rute Fernandes, Diogo Fonseca, Cristina Oliveira, Ana Rodrigues
    Cureus.2022;[Epub]     CrossRef
  • Management of patients with synchronous head-and-neck and lung cancers
    Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, Laurence Bigay Game, Anne Marie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, Christos Chouaïd
    Journal of Cancer Research and Therapeutics.2022; 18(Suppl 2): S160.     CrossRef
  • Multiple primary malignancies involving lung cancer: a single-center experience
    Luigi Ventura, Paolo Carbognani, Letizia Gnetti, Maurizio Rossi, Marcello Tiseo, Enrico Maria Silini, Nicola Sverzellati, Mario Silva, Marcello Succi, Cesare Braggio, Sara Cattadori, Giovanni Bocchialini, Valeria Balestra, Michele Rusca, Luca Ampollini
    Tumori Journal.2021; 107(3): 196.     CrossRef
  • A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
    Matthew I Ebia, Stephen Capone, Charité Ricker, Jacob S Thomas, Varsha Tulpule, Irene Kang, Anishka D'Souza, David R Freyer, Kimberly Miller, Gino K In
    Cureus.2021;[Epub]     CrossRef
  • A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
    Ali Khalifa, Arkady Broder
    Cureus.2021;[Epub]     CrossRef
  • Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
    Xiaolong Hu, Hongqi Li, Xiaoli Kang, Xuan Wang, Haifeng Pang, Chen Liu, Jianchun Zhang, Yingjie Wang
    Cancer Management and Research.2021; Volume 13: 9247.     CrossRef
  • Synergistic Effect of Lymphatic Invasion and Venous Invasion on the Risk of Lymph Node Metastasis in Patients with Non-Curative Endoscopic Resection of Early Gastric Cancer
    Hye Jin Kang, Hyunsoo Chung, Sang Gyun Kim, Jung Kim, Jue Lie Kim, Eunwoo Lee, Hyun Chae Jung
    Journal of Gastrointestinal Surgery.2020; 24(7): 1499.     CrossRef
  • Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature
    Estefania Beltran, Juan Esteban Garcia-Robledo, Lisa X. Rodríguez-Rojas, Martin Rengifo, Bladimir Perez, Harry Pachajoa, Angela R. Zambrano
    Journal of Medical Case Reports.2020;[Epub]     CrossRef
  • Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
    Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S
    The Lancet Oncology.2020; 21(1): e18.     CrossRef
  • Rare heterochronous liver and pancreatic multiple primary cancers: a case report and literature review
    Wangjun Zhang, Fan Xiao, Jie Li, Xiaoyu Guo, Zhitao Lin, Zijian Huang, Ning Mao, Bei Sun, Gang Wang
    Zeitschrift für Gastroenterologie.2020; 58(11): 1094.     CrossRef
  • Gastric carcinoma and renal cell carcinoma as an atypical presentation of multiple primary malignancies: a case report and review of the literature
    J. A. Martín-Pérez, C. Torres-Silva, R. Tenorio-Arguelles, D. A. García-Corona, S. Silva-González, J. A. Dominguez-Rodriguez, I. De Alba-Cruz, J. F. Nagore-Ancona, J. A. González-Luna, K. A. López-Bochm
    Journal of Medical Case Reports.2020;[Epub]     CrossRef
  • Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
    Alexios-Fotios A. Mentis, Efthimios Dardiotis
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A case report of cholangiocarcinoma combined with moderately differentiated gastric adenocarcinoma
    Yan-Hui Yang, Qing Deng, Tian-Bao Yang, Yang Gui, Yu-xiang Zhang, Jiang-Bo Liu, Qian Deng, Wei-Feng Liu, Jun-Jun Sun
    Medicine.2019; 98(30): e16332.     CrossRef
  • Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries
    Asta Agasarova, Clare Harnett, Niall Mulligan, Muhammad Shakeel Majeed, Alberto Caimo, Gianluca Tamagno
    International Journal of Endocrinology.2018; 2018: 1.     CrossRef
  • Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer
    Ji-Hyeon Park, Jeong-Heum Baek, Jun-Young Yang, Won-Suk Lee, Woon-Kee Lee
    Korean Journal of Clinical Oncology.2018; 14(2): 83.     CrossRef
  • Synchronous primary of periampullary and lung cancer: A case report and review of literature
    Vikas Talreja, Vanita Noronha, Amit Joshi, Vijay Patil, Kumar Prabhash
    Cancer Research, Statistics, and Treatment.2018; 1(2): 173.     CrossRef
  • Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report
    Huijie Fan, Pei Lu, Li Xu, Yanru Qin, Jing Li
    BMC Cancer.2017;[Epub]     CrossRef
  • Multiple primary malignancies involving lung cancer
    Feng Li, Wen-Zhao Zhong, Fei-Yu Niu, Ning Zhao, Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu
    BMC Cancer.2015;[Epub]     CrossRef
  • Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma
    Kenichiro Yabuki, Akira Kubota, Choichi Horiuchi, Takahide Taguchi, Goshi Nishimura, Masahiko Inamori
    European Archives of Oto-Rhino-Laryngology.2013; 270(2): 727.     CrossRef
  • 12,152 View
  • 98 Download
  • 27 Crossref
Close layer
The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
Ha-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo
Cancer Res Treat. 2010;42(4):225-234.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.225
AbstractAbstract PDFPubReaderePub
Purpose

AMD3100, an antagonist of the CXCR4 chemokine receptor is soon to be used clinically for the peripheral mobilization of hematopoietic stem cells (HSCs) in patients with multiple myeloma. AMD3100 has been shown to activate a G protein coupled with CXCR4 and thus acts as a partial CXCR4 agonist in vitro. Thus, we explored whether AMD3100 affected the survival and proliferation of myeloma cells in vitro.

Materials and Methods

The effects of AMD3100 on survival and proliferation of two myeloma cell lines (RPMI8226 and U266) as well as CD138+ cells obtained from several patients with multiple myeloma were analyzed by flow cytometry using annexin V and a colorimetric cell proliferation assay (CCK-8 assay).

Results

AMD3100, but not T140, another CXCR4 antagonist, stimulated the proliferation of myeloma cell lines and CD138+ primary human myeloma cells (-2-fold increase) in a dose-dependent manner in serum-free culture for up to 5 days, which was inhibited by pretreating the cells with pertussis toxin. AMD3100 enhanced the proliferation of U266 cells induced by interleukin-6 and partially reversed AG490-mediated growth inhibition and apoptosis induced by serum deprivation in RPMI8226 cells. AMD3100 induced the phosphorylation of Akt and MAPK p44/p42 in U266 cells and MAPK p44/p42 in RPMI8226 cells. In contrast, AMD3100 markedly increased the cell apoptosis and reduced the number of RPMI8226 cells after 5 to 7 days of culture under serum-free conditions.

Conclusion

AMD3100 exerts dual effects, initially enhancing and subsequently inhibiting the survival and proliferation of myeloma cells, signaling via CXCR4 in vitro.

Citations

Citations to this article as recorded by  
  • Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles
    Eloi Parladé, Annabel García-Leon, Eric Voltà-Durán, Ugutz Unzueta, Ramon Mangues, Isolda Casanova, Antonio Villaverde, Esther Vázquez
    European Journal of Pharmaceutics and Biopharmaceutics.2024; 202: 114410.     CrossRef
  • Lyophilization of biomimetic amyloids preserves their regulatable, endocrine-like functions for nanoparticle release
    Marianna TP Favaro, Hèctor López-Laguna, Eric Voltà-Durán, Lorena Alba-Castellon, Julieta M. Sánchez, Isolda Casanova, Ugutz Unzueta, Ramón Mangues, Antonio Villaverde, Esther Vázquez
    Applied Materials Today.2024; 39: 102348.     CrossRef
  • Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials
    Naroa Serna, Aïda Falgàs, Annabel García-León, Ugutz Unzueta, Yáiza Núñez, Alejandro Sánchez-Chardi, Carlos Martínez-Torró, Ramón Mangues, Esther Vazquez, Isolda Casanova, Antonio Villaverde
    Pharmaceutics.2022; 14(1): 192.     CrossRef
  • Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging
    Hua Yang, Shanshan Tan, Jingjuan Qiao, Yiting Xu, Zongxiang Gui, Yuguang Meng, Bin Dong, Guangda Peng, Oluwatosin Y. Ibhagui, Weiping Qian, Jimmy Lu, Zezhong Li, Guimin Wang, Jinping Lai, Lily Yang, Hans E. Grossniklaus, Jenny J. Yang
    Cancer Gene Therapy.2022; 29(12): 1827.     CrossRef
  • Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering
    Eric Voltà-Durán, Olivia Cano-Garrido, Naroa Serna, Hèctor López-Laguna, Laura Sánchez-García, Mireia Pesarrodona, Alejandro Sánchez-Chardi, Ramón Mangues, Antonio Villaverde, Esther Vázquez, Ugutz Unzueta
    Science China Materials.2020; 63(1): 147.     CrossRef
  • Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci
    María Virtudes Céspedes, Olivia Cano‐Garrido, Patricia Álamo, Rita Sala, Alberto Gallardo, Naroa Serna, Aïda Falgàs, Eric Voltà‐Durán, Isolda Casanova, Alejandro Sánchez‐Chardi, Hèctor López‐Laguna, Laura Sánchez‐García, Julieta M. Sánchez, Ugutz Unzueta,
    Advanced Materials.2020;[Epub]     CrossRef
  • Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles
    Naroa Serna, Julieta M Sánchez, Ugutz Unzueta, Laura Sánchez-García, Alejandro Sánchez-Chardi, Ramón Mangues, Esther Vázquez, Antonio Villaverde
    Nanotechnology.2019; 30(11): 115101.     CrossRef
  • The Involvement of SDF-1α/CXCR4 Axis in Radiation-Induced Acute Injury and Fibrosis of Skin
    Jinming Cao, Wei Zhu, Daojiang Yu, Lu Pan, Li Zhong, Yuji Xiao, Yiying Gao, Yang Jiao, Qi Zhang, Jiang Ji, Hongying Yang, Shuyu Zhang, Jianping Cao
    Radiation Research.2019; 192(4): 410.     CrossRef
  • Chemokine-mimetic plerixafor derivative for tumor-specific delivery of nanomaterials
    Seungbeom Ko, Gayong Shim, Jinyoung Kim, Yu-Kyoung Oh
    Nano Research.2018; 11(4): 2159.     CrossRef
  • Protein Nanoparticles are nontoxic, Tuneable Cell Stressors
    Marianna Teixeira de Pinho Favaro, Laura Sánchez-García, Alejandro Sánchez-Chardi, Mónica Roldán, Ugutz Unzueta, Naroa Serna, Olivia Cano-Garrido, Adriano Rodrigues Azzoni, Neus Ferrer-Miralles, Antonio Villaverde, Esther Vázquez
    Nanomedicine.2018; 13(3): 255.     CrossRef
  • Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs
    Laura Sánchez-García, Naroa Serna, Patricia Álamo, Rita Sala, María Virtudes Céspedes, Mònica Roldan, Alejandro Sánchez-Chardi, Ugutz Unzueta, Isolda Casanova, Ramón Mangues, Esther Vázquez, Antonio Villaverde
    Journal of Controlled Release.2018; 274: 81.     CrossRef
  • The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
    Philipp Berning, Christiane Schaefer, Dagmar Clemens, Eberhard Korsching, Uta Dirksen, Jenny Potratz
    Cell Communication and Signaling.2018;[Epub]     CrossRef
  • Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides
    Marianna Teixeira de Pinho Favaro, Naroa Serna, Laura Sánchez-García, Rafael Cubarsi, Mónica Roldán, Alejandro Sánchez-Chardi, Ugutz Unzueta, Ramón Mangues, Neus Ferrer-Miralles, Adriano Rodrigues Azzoni, Esther Vázquez, Antonio Villaverde
    Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(6): 1777.     CrossRef
  • The inhibitory effects and mechanisms of 3,6-O-sulfated chitosan against human papillomavirus infection
    Yanyun Gao, Wei Liu, Wei Wang, Xiaoshuang Zhang, Xia Zhao
    Carbohydrate Polymers.2018; 198: 329.     CrossRef
  • CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases
    Tianci Chu, Lisa B. E. Shields, Yi Ping Zhang, Shi-Qing Feng, Christopher B. Shields, Jun Cai
    The Neuroscientist.2017; 23(6): 627.     CrossRef
  • Hypoxia and hyperoxia differentially control proliferation of rat neural crest stem cells via distinct regulatory pathways of the HIF1α–CXCR4 and TP53–TPM1 proteins
    Chien‐Cheng Chen, Ching‐Wu Hsia, Cheng‐Wen Ho, Chang‐Min Liang, Chieh‐Min Chen, Kun‐Lun Huang, Bor‐Hwang Kang, Yi‐Hui Chen
    Developmental Dynamics.2017; 246(3): 162.     CrossRef
  • CXCL12 and CXCR7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma
    Johannes M. Waldschmidt, Anna Simon, Dagmar Wider, Stefan J. Müller, Marie Follo, Gabriele Ihorst, Sarah Decker, Joschka Lorenz, Manik Chatterjee, Abdel K. Azab, Justus Duyster, Ralph Wäsch, Monika Engelhardt
    British Journal of Haematology.2017; 179(1): 36.     CrossRef
  • CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth
    Patrick M. Reeves, Mojgan A. Abbaslou, Farah R.W. Kools, Mark C. Poznansky
    Anti-Cancer Drugs.2017; 28(9): 935.     CrossRef
  • AMD3100: A Versatile Platform for CXCR4 Targeting 68Ga-Based Radiopharmaceuticals
    Sophie Poty, Eleni Gourni, Pauline Désogère, Frédéric Boschetti, Christine Goze, Helmut R. Maecke, Franck Denat
    Bioconjugate Chemistry.2016; 27(3): 752.     CrossRef
  • The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
    Linn Reinholdt, Maria Bach Laursen, Alexander Schmitz, Julie Støve Bødker, Lasse Hjort Jakobsen, Martin Bøgsted, Hans Erik Johnsen, Karen Dybkær
    Biomarker Research.2016;[Epub]     CrossRef
  • PCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells
    Shuguang Zhang, Guan Sun, Zhimin Wang, Yi Wan, Jun Guo, Lei Shi
    Tumor Biology.2015; 36(3): 1455.     CrossRef
  • Chemokines and Bone
    Annette Gilchrist, Paula H. Stern
    Clinical Reviews in Bone and Mineral Metabolism.2015; 13(2): 61.     CrossRef
  • AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments
    YU-XIN LIAO, ZE-ZE FU, CHENG-HAO ZHOU, LIAN-CHENG SHAN, ZHUO-YING WANG, FEI YIN, LONG-PO ZHENG, YING-QI HUA, ZHENG-DONG CAI
    Oncology Reports.2015; 34(1): 33.     CrossRef
  • CXC Chemokine Ligand 12 Protects Pancreatic β-Cells from Necrosis through Akt Kinase-Mediated Modulation of Poly(ADP-ribose) Polymerase-1 Activity
    Nevena Grdović, Svetlana Dinić, Mirjana Mihailović, Aleksandra Uskoković, Jelena Arambašić Jovanović, Goran Poznanović, Ludwig Wagner, Melita Vidaković, Malka Cohen-Armon
    PLoS ONE.2014; 9(7): e101172.     CrossRef
  • Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study
    Wenli Zheng, Dingshen Liu, Xiangshan Fan, Linda Powers, Maitrayee Goswami, Ying Hu, Pei Lin, L. Jeffrey Medeiros, Sa A. Wang
    Cytometry Part B: Clinical Cytometry.2013; 84B(4): 222.     CrossRef
  • Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology
    Katharina Lückerath, Constantin Lapa, Annika Spahmann, Gerhard Jörg, Samuel Samnick, Andreas Rosenwald, Herrmann Einsele, Stefan Knop, Andreas K. Buck, Evren Alici
    PLoS ONE.2013; 8(12): e84840.     CrossRef
  • An Antedrug of the CXCL12 Neutraligand Blocks Experimental Allergic Asthma without Systemic Effect in Mice
    François Daubeuf, Muriel Hachet-Haas, Patrick Gizzi, Vincent Gasparik, Dominique Bonnet, Valérie Utard, Marcel Hibert, Nelly Frossard, Jean-Luc Galzi
    Journal of Biological Chemistry.2013; 288(17): 11865.     CrossRef
  • EETs and CYP2J2 inhibit TNF-α-induced apoptosis in pulmonary artery endothelial cells and TGF-β1-induced migration in pulmonary artery smooth muscle cells
    WENJING FENG, XIZHEN XU, GANG ZHAO, GENG LI, TIANTIAN LIU, JUNJIE ZHAO, RUOLAN DONG, DAO WEN WANG, LING TU
    International Journal of Molecular Medicine.2013; 32(3): 685.     CrossRef
  • The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review)
    YU-XIN LIAO, CHENG-HAO ZHOU, HUI ZENG, DONG-QING ZUO, ZHUO-YING WANG, FEI YIN, YING-QING HUA, ZHENG-DONG CAI
    International Journal of Molecular Medicine.2013; 32(6): 1239.     CrossRef
  • Why and how to find neutraligands targeting chemokines?
    Jean-Luc Galzi, Muriel Haas, Nelly Frossard, Marcel Hibert
    Drug Discovery Today: Technologies.2012; 9(4): e245.     CrossRef
  • Sublytic C5b‐9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy‐1 nephritis through TRAF6‐mediated PI3K‐dependent Akt1 activation
    Wen Qiu, Yan Zhang, Xiaomei Liu, Jianbo Zhou, Yan Li, Ying Zhou, Kai Shan, Mei Xia, Nan Che, Xuefeng Feng, Dan Zhao, Yingwei Wang
    The Journal of Pathology.2012; 226(4): 619.     CrossRef
  • Initial Assessment of the Role of CXC Chemokine Receptor 4 after Polytrauma
    Harold H. Bach, Vikas Saini, Todd A. Baker, Abhishek Tripathi, Richard L. Gamelli, Matthias Majetschak
    Molecular Medicine.2012; 18(7): 1056.     CrossRef
  • Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cellsin vitro
    Ha-Yon Kim, Ji-Young Hwang, Yoon-Suk Oh, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Young-Jun Yang, Deog-Yeon Jo
    The Korean Journal of Hematology.2011; 46(4): 244.     CrossRef
  • 11,638 View
  • 80 Download
  • 33 Crossref
Close layer
Case Reports
A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy
Gun Min Kim, Hei-Cheul Jeung, Dokyung Kim, Joo Hoon Kim, Sang Hyun Yoon, Eun Suk Jung, Sang Joon Shin
Cancer Res Treat. 2010;42(4):235-238.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.235
AbstractAbstract PDFPubReaderePub

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2. After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

Citations

Citations to this article as recorded by  
  • Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
    Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
    Liver Cancer.2024; 13(1): 6.     CrossRef
  • A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery
    Feng Zhang, Keshu Hu, Bei Tang, Mengxin Tian, Shenxin Lu, Jia Yuan, Miao Li, Rongxin Chen, Zhenggang Ren, Yinghong Shi, Xin Yin
    Journal of Gastrointestinal Surgery.2021; 25(4): 971.     CrossRef
  • Treatment of Combined Hepatocellular and Cholangiocarcinoma
    Simona Leoni, Vito Sansone, Stefania De Lorenzo, Luca Ielasi, Francesco Tovoli, Matteo Renzulli, Rita Golfieri, Daniele Spinelli, Fabio Piscaglia
    Cancers.2020; 12(4): 794.     CrossRef
  • Therapy of Primary Liver Cancer
    Mei Feng, Yisheng Pan, Ruirui Kong, Shaokun Shu
    The Innovation.2020; 1(2): 100032.     CrossRef
  • Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
    Yuka Futsukaichi, Kazuto Tajiri, Saito Kobayashi, Kohei Nagata, Satoshi Yasumura, Terumi Takahara, Masami Minemura, Ichiro Yasuda
    Clinical Journal of Gastroenterology.2019; 12(2): 128.     CrossRef
  • Clinical and pathological features of combined hepatocellular–cholangiocarcinoma compared with other liver cancers
    Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Masafumi Ohira, Koichi Kato, Yuki Fujii, Ko Sugiyama, Naoki Okada, Takanori Ohata, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Akinobu Taketomi
    Journal of Gastroenterology and Hepatology.2019; 34(6): 1074.     CrossRef
  • Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score–Matched Study
    Yu-Hui Huang, Benjamin V. Park, Yi-Fan Chen, Ron C. Gaba, Grace Guzman, R. Peter Lokken
    Journal of Vascular and Interventional Radiology.2019; 30(9): 1317.     CrossRef
  • Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
    Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigu
    Cancer Science.2018; 109(8): 2549.     CrossRef
  • Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma
    Lauren S. Chan, Daniel Y. Sze, George A. Poultsides, John D. Louie, Mohammed A. Abdelrazek Mohammed, David S. Wang
    CardioVascular and Interventional Radiology.2017; 40(9): 1383.     CrossRef
  • A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy
    Jee Eun Choi, Kyung Hee Kim, Seon A Kim, Jung Hwan Lee, Sang Myung Woo, Sang-Jae Park, Eun Kyung Hong, Woo Jin Lee
    Korean Journal of Pancreas and Biliary Tract.2016; 21(2): 101.     CrossRef
  • Combined hepatocellular cholangiocarcinoma: Controversies to be addressed
    An-Qiang Wang
    World Journal of Gastroenterology.2016; 22(18): 4459.     CrossRef
  • Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy
    Kathryn Fowler, Nael E. Saad, Elizabeth Brunt, M. B. Majella Doyle, Manik Amin, Neeta Vachharajani, Benjamin Tan, William C. Chapman
    Annals of Surgical Oncology.2015; 22(13): 4130.     CrossRef
  • Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity
    Kate O’Connor, Joanna C. Walsh, David F. Schaeffer
    Annals of Hepatology.2014; 13(3): 317.     CrossRef
  • Transplantation versus resection for patients with combined hepatocellular carcinoma–cholangiocarcinoma
    Ryan T. Groeschl, Kiran K. Turaga, T. Clark Gamblin
    Journal of Surgical Oncology.2013; 107(6): 608.     CrossRef
  • 11,003 View
  • 81 Download
  • 14 Crossref
Close layer
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Initially Mimicking Cutaneous Lupus Erythematosus
Hye Jung Chang, Myung Dong Lee, Hyeon Gyu Yi, Joo Han Lim, Moon Hee Lee, Jeong Hyun Shin, Suk Jin Choi, Yeonsook Moon, Chung Hyun Nahm, Chul Soo Kim
Cancer Res Treat. 2010;42(4):239-243.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.239
AbstractAbstract PDFPubReaderePub

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease. The prognosis is poor in most cases with rapid progression despite administering chemotherapy. A 67-year-old man complained of skin rashes on his back and this spread to the trunk, face, arms and thighs, and he was initially diagnosed with cutaneous lupus erythematosus according to the skin biopsy. The skin rashes then became aggravated on a trial of low dose methylprednisolone for 3 months. Repeated skin biopsy revealed a diffuse infiltration of lymphoid cells with medium sized nuclei, positive for CD4 and CD56, negative for Epstein-Barr virus (EBV), indicating a diagnosis of BPDCN. Further workups confirmed stage IVA BPDCN involving the skin, multiple lymph nodes, the peripheral blood and the bone marrow. He was treated with six cycles of combination chemotherapy consisting of ifosphamide, methotrexate, etoposide, prednisolone and L-asparaginase, and he achieved a partial response. Herein we report on a rare case of BPDCN that was initially misinterpreted as cutaneous lupus erythematosus.

Citations

Citations to this article as recorded by  
  • Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
    Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, Claudia Paganini, Elena Campione, Marco Galluzzo, Luca Bianchi
    International Journal of Molecular Sciences.2024; 25(13): 7099.     CrossRef
  • Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
    Michael Haddadin, Justin Taylor
    Hematology/Oncology Clinics of North America.2020; 34(3): 539.     CrossRef
  • Dendritic Cell Leukemia: a Review
    Nikolaos J. Tsagarakis, Georgios Paterakis
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review
    Marie Jeong-Min Kim, Ahmed Nasr, Bilaal Kabir, Joseph de Nanassy, Ken Tang, Danielle Menzies-Toman, Donna Johnston, Dina El Demellawy
    Journal of Pediatric Hematology/Oncology.2017; 39(7): 528.     CrossRef
  • Simultaneous deletion of 3′ETV6 and 5′EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review
    Zhenya Tang, Guilin Tang, Sa A. Wang, Xinyan Lu, Ken H. Young, Carlos E. Bueso-Ramos, Yesid Alvarado, L. Jeffrey Medeiros, Joseph D. Khoury
    Molecular Cytogenetics.2016;[Epub]     CrossRef
  • NK-Cell Lymphoblastic Leukemia/Lymphoma (Literature Review and Authors' Experience)
    M.A. Frenkel', O.Yu. Baranova, Alina Sergeevna Antipova, N.A. Kupryshina, N.N. Tupitsyn
    Clinical oncohematology.2016; 9(2): 208.     CrossRef
  • Blastic plasmacytoid dendritic neoplasm (BPDN) or BPDN-like lesion presenting after influenza vaccination and resolving with topical high potency steroid
    Jonathan Yao, Joanna Dong, James Strauchen, Rajendra Singh
    JAAD Case Reports.2015; 1(4): 203.     CrossRef
  • Lupus mimickers
    Omar-Javier Calixto, Juan-Sebastian Franco, Juan-Manuel Anaya
    Autoimmunity Reviews.2014; 13(8): 865.     CrossRef
  • Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
    Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Taiga Nishihori, Rami A. Mahfouz, Mehdi Hamadani
    Biology of Blood and Marrow Transplantation.2013; 19(7): 1006.     CrossRef
  • Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature
    Wanzhuo Xie, Yanmin Zhao, Ling Cao, Weijia Huang, Yanli Wang, He Huang
    Medical Oncology.2012; 29(4): 2417.     CrossRef
  • Cutaneous lupus erythematosus: a great imitator
    Ashok Kumar Khare
    Expert Review of Dermatology.2011; 6(6): 555.     CrossRef
  • 12,061 View
  • 81 Download
  • 11 Crossref
Close layer
Reversible Proximal Renal Tubular Dysfunction after One-Time Ifosfamide Exposure
Young Il Kim, Ju Young Yoon, Jun Eul Hwang, Hyun Jeong Shim, Woo Kyun Bae, Sang Hee Cho, Ik-Joo Chung
Cancer Res Treat. 2010;42(4):244-246.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.244
AbstractAbstract PDFPubReaderePub

The alkylating agent ifosfamide is an anti-neoplastic used to treat various pediatric and adult malignancies. Its potential urologic toxicities include glomerulopathy, tubulopathy and hemorrhagic cystitis. This report describes a case of proximal renal tubular dysfunction and hemorrhagic cystitis in a 67-year-old male given ifosfamide for epitheloid sarcoma. He was also receiving an oral hypoglycemic agent for type 2 diabetes mellitus and had a baseline glomerular filtration rate of 51.5 mL/min/1.73 m2. Despite mesna prophylaxis, the patient experienced dysuria and gross hematuria after a single course of ifosfamide plus adriamycin. The abrupt renal impairment and serum/urine electrolyte imbalances that ensued were consistent with Fanconi's syndrome. However, normal renal function and electrolyte status were restored within 14 days, simply through supportive measures. A score of 8 by Naranjo adverse drug reaction probability scale indicated these complications were most likely treatment-related, although they developed without known predisposing factors. The currently undefined role of diabetic nephropathy in adult ifosfamide nephrotoxicity merits future investigation.

Citations

Citations to this article as recorded by  
  • Ifosfamide-induced nephrotoxicity in oncological patients
    Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérre
    Expert Review of Anticancer Therapy.2024; 24(1-2): 5.     CrossRef
  • Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE
    Ahmet Kursad Gunes, Simten Dagdas, Funda Ceran, Mehmet Ali Ucar, Mesude Falay, Cenk Sunu, Meltem Ayli, Nurullah Zengin, Gulsum Ozet
    Indian Journal of Hematology and Blood Transfusion.2021; 37(1): 82.     CrossRef
  • Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
    S. D’Oronzo, S. Stucci, M. Tucci, F. Silvestris
    Cancer Treatment Reviews.2015; 41(9): 798.     CrossRef
  • Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity
    M. Airy, R. Raghavan, L. D. Truong, G. Eknoyan
    Nephrology Dialysis Transplantation.2013; 28(10): 2502.     CrossRef
  • 8,144 View
  • 57 Download
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP